The HIV-associated adipose redistribution syndrome (HARS) study, a phase III, double-blind, placebo-controlled trial, was designed to evaluate recombinant human growth hormone (r-hGH) as a potential therapy for reducing
Schering-Plough reported that results from the ongoing phase II clinical trial showed that vicriviroc, the company’s investigational CCR5 receptor antagonist, demonstrated potent and sustained viral suppression after 24
The primary objective of the phase II open-label study is to assess efficacy of weekly doses of Marqibo (vincristine sulfate liposomes injection) plus pulse dexamethasone as measured by
PRO-571 is a unique, rapid-release formulation of diclofenac potassium in tablet form, which utilizes ProEthic’s Dynamic Buffering Technology (DBT). In two separate phase I studies, each enrolling 36
The Schering-sponsored study, which was named BENEFIT, was a 487-patient, double-blinded, phase III trial. It is the only early two-year MS trial that utilized a high-dose, high-frequency interferon-beta
The company also announced that it has decided to use the name Rhucin as the global trade mark for recombinant human C1 inhibitor (rhC1INH) for the treatment of
AGS-003 is a second-generation dendritic cell-based therapy with optimized immune response characteristics that is designed to stimulate the patient’s immune system to target and destroy the patient’s cancer
The open-label, randomized, two-way crossover, drug-drug interaction study evaluated the impact of Omacor (omega-3-acid ethyl esters) capsules on plasma simvastatin pharmacokinetics in 24 healthy patients. Patients were given
Based on the safety profile and the ability to deliver planned doses of gemcitabine in combination with RP101, an RP101 dose of 750mg/day has been selected to be
ImmuneRegen, a wholly owned subsidiary of IR BioSciences Holdings, is collaborating with Hyperion Biotechnology to perform these tests at Hyperion’s research facility. Initial studies in a well-established mouse
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.